The estimated Net Worth of James Bullock is at least $788 mil dollars as of 16 September 2020. Mr. Bullock owns over 10,000 units of Artivion Inc stock worth over $608,331 and over the last 8 years he sold CRY stock worth over $0. In addition, he makes $180,015 as Independent Director at Artivion Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Bullock CRY stock SEC Form 4 insiders trading
James has made over 1 trades of the Artivion Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of CRY stock worth $166,300 on 16 September 2020.
The largest trade he's ever made was buying 10,000 units of Artivion Inc stock on 16 September 2020 worth over $166,300. On average, James trades about 1,429 units every 0 days since 2017. As of 16 September 2020 he still owns at least 34,023 units of Artivion Inc stock.
You can see the complete history of Mr. Bullock stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Bullock biography
James W. Bullock is Independent Director of the Company, Mr. Bullock has served as a director of CryoLife since October 2016. Mr. Bullock previously served as the President and Chief Executive Officer of Zyga Technology, Inc. (“Zyga Technology”), a privately-held medical device company focused on products that treat conditions of the lumbar spine, until January 2018, when RTI Surgical, Inc. (NASDAQ: RTIX) acquired Zyga Technology. Prior to that, he served for six years as President and Chief Executive Officer of Atritech, Inc. Atritech was a privately-held cardiovascular manufacturing company that was acquired by Boston Scientific (NYSE: BSX). Prior to that, he served for nine years as President and Chief Executive Officer and was a member of the board of directors of Endocardial Solutions, Inc. (NASDAQ: ECSI), a cardiac-focused medical device company that was acquired by St. Jude Medical, which was itself acquired by Abbott Laboratories (NYSE: ABT). He also served in that position at Stuart Medical, Inc., and began his career working in a variety of sales and marketing leadership positions at Baxter Healthcare, Inc. (NYSE: BAX), and American Hospital Supply Corporation. In addition to his service on the board of Endocardial Solutions, Inc., Mr. Bullock has also served on the boards of directors of several private companies. Currently, in addition to CryoLife’s Board of Directors, Mr. Bullock also serves as Chairman of the board of directors of Stimdia, Inc., a privately-held company that is conducting research for the development of medical devices for use in the critical care treatment of ventilator induced diaphragmatic dysfunction. Mr. Bullock also serves as a director for Surgical Information Science, Inc., a private health company, and CardioNxt, Inc., a private health company. Mr. Bullock received a B.S. in Public Administration from the University of Arizona.
What is the salary of James Bullock?
As the Independent Director of Artivion Inc, the total compensation of James Bullock at Artivion Inc is $180,015. There are 15 executives at Artivion Inc getting paid more, with James Mackin having the highest compensation of $6,453,540.
How old is James Bullock?
James Bullock is 63, he's been the Independent Director of Artivion Inc since 2016. There are 5 older and 18 younger executives at Artivion Inc. The oldest executive at Artivion Inc is Ronald McCall, 83, who is the Presiding Independent Director.
What's James Bullock's mailing address?
James's mailing address filed with the SEC is CRYOLIFE, INC., 1655 ROBERTS BLVD NW, KENNESAW, GA, 30144.
Insiders trading at Artivion Inc
Over the last 21 years, insiders at Artivion Inc have traded over $18,346,910 worth of Artivion Inc stock and bought 91,700 units worth $1,086,548 . The most active insiders traders include Steven G Anderson, Thomas F Ackerman y James P Mackin. On average, Artivion Inc executives and independent directors trade stock every 26 days with the average trade being worth of $211,842. The most recent stock trade was executed by Amy Horton on 8 December 2021, trading 2,500 units of CRY stock currently worth $46,425.
What does Artivion Inc do?
Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. CryoLife markets and sells products in more than 100 countries worldwide.
What does Artivion Inc's logo look like?
Complete history of Mr. Bullock stock trades at Artivion Inc
Artivion Inc executives and stock owners
Artivion Inc executives and other stock owners filed with the SEC include:
-
James Mackin,
Chairman of the Board, President, Chief Executive Officer, Director -
D. Ashley Lee,
Chief Financial Officer, Chief Operating Officer, Executive Vice President -
Jean Holloway,
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary -
Michael Simpson,
Senior Vice President - Regulatory Affairs and Quality Assurance -
John Davis,
Senior Vice President - Global Sales and Marketing -
James Patrick Mackin,
Chairman, Pres & CEO -
Scott Capps,
Vice President - Clinical Research -
David Ashley Lee CPA, CPA,
Exec. VP, COO & CFO -
Jean F. Holloway Esq.,
Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
John E. Davis,
Sr. VP of Global Sales & Marketing -
Harvey Morgan,
Independent Director -
Daniel Bevevino,
Independent Director -
Ronald McCall,
Presiding Independent Director -
Thomas Ackerman,
Independent Director -
Jon Salveson,
Independent Director -
James Bullock,
Independent Director -
Jeffrey Burbank,
Independent Director -
Marna Borgstrom,
Independent Director -
Greg Chodaczek,
IR Contact Officer -
Matthew Getz,
Vice President - Human Resources -
Dennis Maier,
Vice President - Operations -
Amy Horton,
Chief Accounting Officer, Vice President -
Thomas Bogenschutz,
Senior Vice President - EMEA, General Manager - Hechingen -
Dr. Marshall S. Stanton,
Sr. VP of Clinical Research & Chief Medical Officer -
Joshua Wells,
Sr. Director of Bus. Devel. -
Matthew A. Getz,
VP of HR -
Amy D. Horton CPA, CPA,
VP & Chief Accounting Officer -
Sherry M Saurini,
VP, Quality -
C Elkins Ronald,
Director -
James Benson,
Director -
James M Mc Dermid,
SVP, CHRO -
David C Gale,
VP-Research and Development -
William Robert Matthews,
Senior VP, Operations, Quality -
Thomas J Bogenschuetz,
VP, EMEA & General Manager -
Bruce G. Anderson,
VP, US Sales and Marketing -
Jeffrey W Burris,
Vice President & Gen. Counsel -
Gerald B Seery,
Sr. VP, Sales and Marketing -
John M Cook,
Director -
David P. Lang,
Sr. VP, Intl Sales & Marketing -
Steven G Anderson,
President, CEO and Chairman -
Thomas J Lynch,
VP - Reg. Aff./Quality Assur. -
Capital Management Oss,
10% owner -
Philip A Theodore,
VP, General Counsel -
Michaelstark Brian Jay Roth,
-
Sidney B Ashmore,
Vice President of Marketing -
Virginia C Lacy,
Director -
Dyne Bruce J Md Van,
Director -
Albert E Heacox,
Sr. VP-Laboratory Operations -
Vander James C Wyk,
VP - Product Integrity -
Kirby S Black,
Sr. Vice President, R&D -
David Fronk,
VP - Clinical Research -
Rochelle L. Maney,
VP, Quality -
Franz Peter Barthold,
VP, Research & Development -
Marshall S. Stanton,
SVP, Clinical & MD Affair -
Anthony B. Semedo,
Director